Document is current

Article History

Received: 14 November 2022

Accepted: 29 June 2023

First Online: 15 July 2023

Competing interests

: N.S. reports research funding from Novartis and Varian. M.M.A serves as a consultant to Merck, Bristol-Myers Squibb, Genentech, AstraZeneca, Nektar, Maverick, Blueprint Medicine, Syndax, Abbvie, Gritstone, ArcherDX, Mirati, NextCure, and EMD Serono. Research Funding: Bristol-Myers Squibb, Lilly, Genentech, and AstraZeneca. B.E.J. receives post marketing royalties for EGFR mutation testing from Dana-Farber Cancer Institute, is a paid consultant to Novartis, Checkpoint Therapeutics, Hummingbird Diagnostics, Daichi Sankyo, Astra Zeneca, G1 Therapeutics, BlueDotBio, GSK, Hengrui Therapeutics, Simcere Pharmaceutical, and unpaid member of a steering committee for Pfizer, and receives research support from Novartis and Cannon Medical Imaging. D.R.G. has received consulting fees from Johnson and Johnson, Medtronic, AstraZeneca, and GRAIL. He has received honoraria from MedLearning Group and Varian. He has received research funding from Varian and AstraZeneca. E.S.L. has an equity interest and fiduciary role in Oncia Technologies. A.R. reports grants from Varian Medical Systems, Boehringer Ingelheim, Pfizer, Astra Zeneca, and Merck in addition to personal fees from Astra Zeneca, Merck, Cybrexa, Research to Practice, and MoreHealth, and reports non-financial support from Philips/Elekta. A.J.S reports grants from GSK, PACT pharma, Iovance Biotherapeutics, Achilles Therapeutics, Merck, and Harpoon Therapeutics and consulting fees from J&J, KSQ Therapeutics, BMS, Enara Bio, Perceptive Advisors, and Heat Biologics. J.E.C. reports grants from Merck, Brystol Myers Squibb, Genentech, and AstraZeneca. S.J.R. receives research funding from Bristol-Myers-Squibb and KITE/Gilead. S.J.R. is a member of the SAB of Immunitas Therapeutics. J.V.A., B.R., X.W., A.E., G.L., A.D.F., E.S.L., M.T., and F.P.: Nothing to disclose.